FDA Approves TheraSphere Y-90 Glass Microspheres for Patients With HCC

On March 18, 2021, Boston Scientific Corporation announced it received approval from the U.S. Food and Drug Administration (FDA) for the TheraSphere™ Y-90 Glass Microspheres for the treatment of patients with hepatocellular carcinoma (HCC). TheraSphere is the only radioembolization technology indicated for the treatment of unresectable HCC in the United States.

Read Boston Scientific Corporation's announcement.

Posted 3/19/2021